Top Injectable Manufacturer in Nepal – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 3 days ago
- 10 min read
Last Updated: July 22, 2026
TL;DR: Nepal is a market of close to 30 million people that imports well over half of the medicines it consumes and depends on India for the overwhelming majority of those imports — India also supplies effectively all of the active pharmaceutical ingredients Nepali factories use. Demand for sterile injectables is driven by a striking epidemiological shift: non-communicable diseases now account for roughly 71% of deaths, cardiovascular disease alone for about a quarter, cancer for an estimated 22,000 new cases a year, and tuberculosis for some 67,000; road-traffic trauma kills more than 2,300 people annually, and the monsoon brings a seasonal surge in snakebite that leans almost entirely on imported polyvalent antivenom. Market access runs through the Department of Drug Administration (DDA) under the Ministry of Health and Population, whose Medicine Registration Guidance requires a foreign manufacturer to be approved and WHO-GMP certified — with the DDA inspecting the Indian plant itself, because India is not a stringent-regulatory-authority country — before any product is registered for two years through a Nepali authorised importer. Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at a WHO-GMP certified, ISO Class 5 facility in Gujarat, India, exports to over 30 countries, and supports Nepali partners with CTD dossiers, WHO-format CPPs, Zone IVb stability data and inspection-ready plant access.
Key Takeaways
Two gates, not one. DDA registration is a two-stage process: under the Medicine Registration Guidance the foreign manufacturer is first approved as a company (a Site Master File in PIC/S structure, a valid WHO-GMP certificate, a GMP audit and a product dossier), and only then is each product registered and granted an import recommendation letter. WHO-GMP certification of the plant is compulsory throughout.
The DDA inspects the Indian factory. Because India is not classified as a stringent regulatory authority, a valid Indian WHO-GMP certificate and a notarised Certificate of Pharmaceutical Product are necessary but not sufficient: the DDA conducts its own on-site GMP inspection of the manufacturing site before registration — a regime made vivid by the December 2022 blacklisting of sixteen Indian companies after DDA inspectors visited India. A manufacturer that can host and pass that inspection is in a materially stronger position.
You cannot import directly, and registration lasts two years. Importation is reserved to a Nepali DDA-registered wholesaler, which must be authorised by the foreign manufacturer through a Letter of Attorney and which files the application; a product registration is valid for two years and must be renewed — not the five-year term common in other markets — so renewal planning matters.
Stability is Zone IVb and dossiers are in English. The DDA’s product-registration checklist explicitly calls for real-time stability at ICH Climatic Zone IVb (30°C/75% RH) on two batches for the claimed shelf life, and the registration dossier is prepared in English — both natural fits for an Indian manufacturer. Bioequivalence is not required for intravenous injections.
Introduction: Why an Injectable Manufacturer in Nepal Must Meet Global Standards
Nepal’s health system serves close to 30 million people through a federal structure of central, provincial and local government, with public medicines forecast, procured, stored and distributed by the Management Division of the Department of Health Services under the Ministry of Health and Population. Procurement is anchored to the National List of Essential Medicines — 398 molecules in its sixth revision — and to a free essential-drugs programme that supplies a defined basket at no charge through public facilities, while tertiary and teaching hospitals run their own tenders and use drug and therapeutic committees to authorise products for hospital use. The country has a real domestic industry — on the order of sixty human-medicine factories that now meet roughly 45% of the market, including local parenteral makers such as Lomus Parenterals and Everest Parenterals — yet it still imports well over half of its finished medicines and depends on India for effectively all of its active pharmaceutical ingredients. For a sterile injectable supplier, that combination of genuine local capability and deep import dependence defines the opportunity: the market rewards a partner that competes on documentation, quality and reliability rather than on mere availability.
The demand behind that dependence is shifting fast. Non-communicable diseases now cause roughly 71% of all deaths in Nepal, with cardiovascular disease alone responsible for about a quarter, and cancer accounting for an estimated 22,000 new cases and around 14,700 deaths a year — a profile that pulls demand toward injectable oncology, cardiovascular and critical-care medicines. Tuberculosis remains heavy at an estimated 67,000 cases a year against far fewer notifications, road-traffic trauma kills more than 2,300 people annually and fills surgical and emergency wards, maternal mortality stands at 151 per 100,000 live births, and each monsoon brings a seasonal surge of snakebite — on the order of 20,000 bites and around 1,000 deaths a year — that leans almost entirely on imported polyvalent antivenom from India. Across all of it, the injectable essentials — anaesthetics, antibiotics, oxytocics, emergency and critical-care drugs — have to arrive sterile, correctly documented and exactly to specification, batch after batch. Nepal needs reliable imported sterile injectables from manufacturers whose quality systems will survive an inspection.
What Sets a World-Class Injectable Manufacturer in Nepal Apart
The first differentiator is genuine sterile-manufacturing capability rather than a general plant with a filling line bolted on. Sterile injectables bypass every natural barrier the body has, so sterility assurance cannot be inferred from a finished-product test alone — it has to be designed into the facility. Farbe Firma’s operation in Gujarat, India is built around ISO Class 5 aseptic filling zones within classified surrounding areas, unidirectional personnel and material flows, validated terminal sterilisation or aseptic processing according to the molecule, routine media-fill validation, environmental and personnel monitoring with trended data, and Water-for-Injection generation and distribution held under continuous control. That architecture is what turns a certificate of analysis into a defensible claim — and, because the Department of Drug Administration inspects the manufacturing site itself before it will register a product, it is precisely what a DDA inspector arriving from Kathmandu will be looking for.
The second differentiator is market-access support built around Nepal’s actual pathway, which has two gates rather than one. Under the DDA’s Medicine Registration Guidance, a foreign manufacturer must first be approved as a company — submitting a Site Master File in PIC/S structure, a valid WHO-GMP certificate, a GMP self-audit and a dossier of at least one product — before any of its products can be registered and granted an import recommendation letter. WHO-GMP certification of the plant is compulsory, and because India is not classified as a stringent regulatory authority, an Indian WHO-GMP certificate and a notarised Certificate of Pharmaceutical Product are necessary but not sufficient: the DDA conducts its own on-site GMP inspection of the Indian factory. That regime is not theoretical — in December 2022 the DDA blacklisted sixteen Indian companies after its inspectors visited India. Nor can a manufacturer import in its own name: importation is reserved to a Nepali DDA-registered wholesaler authorised through a Letter of Attorney, which files the application. A useful supplier therefore builds the dossier in CTD format, prepares the Site Master File and CPP, hosts the inspection, and supports its Nepali importer through a registration that is valid for two years and renewable.
Quality Systems Behind Every Batch We Ship to Nepal
Every Farbe Firma injectable batch destined for Nepal is released only after the full analytical stack is complete and reviewed. Identity, assay and related substances are determined by HPLC and, where the monograph requires it, GC. Sterility and bacterial endotoxin testing by LAL are performed on every batch, with container-closure integrity and particulate matter assessed against compendial limits, and water content by Karl Fischer titration where the dosage form demands it. Methods are validated to ICH expectations and specifications are set against USP, BP, IP or EP as the market and customer require, with the pharmacopoeial basis stated on the certificate of analysis. Because bioequivalence is not required for intravenous injections, and biowaivers apply to qualifying injectable solutions, the registration effort concentrates where it belongs — on documented sterility, quality and stability.
Behind release testing sits the quality architecture that makes those results meaningful. The DDA’s product-registration checklist calls specifically for real-time stability at ICH Climatic Zone IVb — 30°C/75% RH — on two batches for the claimed shelf life, so our filings are built on completed long-term studies rather than extrapolation, with photostability per ICH Q1B where the molecule warrants it. Change control, deviation management, CAPA, supplier qualification and annual product quality review operate as a connected system rather than as separate files, and batch records are retained so that any vial can be reconstructed from raw material to release years later. Above all, because the DDA inspects the manufacturing site itself, the plant is maintained in a state of continuous inspection readiness — which, given the DDA’s record of acting on what it finds, is not an abstract virtue but a condition of market access.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Nepal for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified facility in Gujarat, India, and exports to over 30 countries. The portfolio spans anti-infectives, oncology support, anaesthesia and analgesia, cardiovascular and critical-care molecules, obstetric medicines, vitamins and parenteral-nutrition adjuncts, delivered as liquid vials, ampoules, lyophilised presentations and small-volume parenterals — closely matching Nepal’s National List of Essential Medicines and the injectable needs of its tertiary hospitals, from emergency and anaesthesia drugs to injectable antibiotics and oncology support. For a Nepali importer assembling a hospital portfolio, or a distributor qualifying for Management Division and hospital tenders, that breadth means one audited manufacturing partner, one documentation standard and one point of accountability rather than a patchwork of sources with uneven paperwork.
Our CDMO services scale from a single importer’s launch portfolio to full tender volumes. Contract and third-party manufacturing runs under the customer’s brand with technology transfer, analytical method transfer, stability commitment and regulatory documentation handled as one package. We prepare the CTD dossier and Site Master File for DDA foreign-manufacturer approval, provide the WHO-GMP certificate and notarised Certificate of Pharmaceutical Product, host the DDA’s on-site inspection, and supply the batch-level certificates of analysis and retention-sample discipline a Nepali importer needs in order to register and defend a product line. Nepal’s open border with India and the long-standing bilateral trade treaty give an Indian manufacturer a genuine logistics advantage — short lead times and overland delivery — provided supply is dependable, a lesson the 2015 border disruption made vivid for Nepali buyers.
Buyers stay with Farbe Firma because we are straightforward about what the Nepali route actually involves. The DDA inspects the Indian plant before it will register a product, registrations run for two years rather than five and have to be renewed on time, and every filing must run through a DDA-registered Nepali importer authorised by us — there is no direct-import shortcut. We are candid, too, about scope: Nepal has banned the import of a number of generic medicines that its own factories make, so we focus on the injectable categories the country genuinely needs to import rather than those it protects, and for Global Fund-financed disease programmes WHO prequalification or stringent-authority approval may be required. What we offer is a plant built to pass the inspection the DDA will actually carry out, documentation shaped to its Medicine Registration Guidance, and the proximity of an Indian manufacturer that can resupply quickly and reliably. We would rather set out the inspection obligation, the two-year renewal cycle and the local-importer requirement honestly at the first meeting than discover the gap at the point of filing.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Nepal?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, producing more than 100 injectable products under ISO Class 5 aseptic conditions and exporting to over 30 countries. For Nepal we prepare the CTD dossier and the Site Master File the Department of Drug Administration requires for foreign-manufacturer approval, provide a valid WHO-GMP certificate and a notarised Certificate of Pharmaceutical Product in WHO format, host the DDA’s on-site inspection of our plant, and hold Zone IVb stability data. Because importation is reserved to a DDA-registered Nepali wholesaler, we work alongside a client’s authorised importer rather than filing in our own name.
How is an imported injectable registered in Nepal, and how long is registration valid?
Registration is a two-stage process under the DDA’s Medicine Registration Guidance. The foreign manufacturer is first approved as a company — on a Site Master File, a valid WHO-GMP certificate, a GMP audit and a product dossier — and each product is then registered and granted an import recommendation letter. The dossier is prepared in CTD format and in English, and the application is filed by a Nepali DDA-registered importer authorised through a Letter of Attorney. Routine processing runs to around six months. A product registration is valid for two years and must be renewed — not the five-year term common in some other markets — so renewal planning matters.
Does the DDA accept an Indian WHO-GMP certificate, or does it inspect the factory itself?
Both are involved, but the certificate alone is not enough. A valid Indian WHO-GMP certificate and a notarised Certificate of Pharmaceutical Product are mandatory, but because India is not classified as a stringent regulatory authority there is no mutual-recognition shortcut: the DDA conducts its own on-site GMP inspection of the Indian manufacturing site before registration. This is a real and active regime — in December 2022 the DDA blacklisted sixteen Indian companies after inspection visits — so a manufacturer that maintains its plant in continuous inspection readiness, as Farbe Firma does, is in a materially stronger position than one that cannot host and pass that inspection.
Which stability data does Nepal require for sterile injectables?
Nepal is treated as ICH Climatic Zone IVb. The DDA’s product-registration checklist specifically calls for real-time stability at 30°C/75% RH on two batches for the full claimed shelf life, supported by accelerated data and, where relevant, an ICH Q1B photostability challenge. Farbe Firma builds this Zone IVb package as standard. Bioequivalence studies are not required for intravenous injections, and biowaivers apply to qualifying injectable solutions, so the registration concentrates on documented sterility, quality and real-time stability rather than clinical-equivalence work.
How does public procurement for injectables work in Nepal?
Government medicines are forecast, procured and distributed by the Management Division of the Department of Health Services under the Ministry of Health and Population, anchored to the National List of Essential Medicines and a free essential-drugs programme delivered through public facilities, with tenders run under the Public Procurement Act. Tertiary and teaching hospitals also run their own tenders and use drug and therapeutic committees to approve products for hospital use. One practical point to plan around: Nepal restricts the import of certain generic medicines that its domestic industry manufactures, so a supplier should confirm a product is import-eligible before investing in its registration — an assessment Farbe Firma helps its importer make at the outset.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments